Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of Matrix Metaloproteinase(MMP)9 and MMP 2 in Risk Stratification for Ventricular Tachycardia/Fibrillation in Patients With Implanted Cardioverter Defibrillator (ICD) Devices.

NCT00376532 is registered in ClinicalTrials.gov with Thomas Jefferson University as lead sponsor.

NCT NCT00376532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00376532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of Matrix Metaloproteinase(MMP)9 and MMP 2 in Risk Stratification for Ventricular Tachycardia/Fibrillation in Patients With Implanted Cardioverter Defibrillator (ICD) Devices.
Lead sponsor
Thomas Jefferson University
Phase
Observational
Overall status
Completed
Start date
September 30, 2006
Completion date
September 30, 2008
Enrollment
63 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

arrythmia, death, sudden, cardiac, ischemia, myocardial, myocardiopathies